Unknown

Dataset Information

Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors.


ABSTRACT:

Importance

New dosing options for immune checkpoint inhibitors have recently been approved by the US Food and Drug Administration (FDA), including fixed dosing with extended intervals. Although the dose intensity appears the same, there is expected to be some waste with extended-interval dosing, as some drug remains in the bloodstream once a decision to stop treatment is made. The economic impact of extended-interval fixed dosing is unknown compared with standard-interval fixed dosing.

Objective

To analyze the potential health care costs of using extended-interval fixed dosing instead of standard-interval fixed dosing.

Design, setting, and participants

This economic evaluation used a pharmacoeconomic model to simulate 2 cohorts of patients with platinum-resistant meta

SUBMITTER: Goldstein DA 

PROVIDER: S-EPMC9951041 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature